Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels

References

• Backman C, Rose GM, Bartus RT, Hoffer BJ, Mufson EJ, Granholm AC. Carrier mediated delivery of NGF: Alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors. J Comp Neurol 1997; 387(1)1–11
   PubMed Web of Science ®Google Scholar
• Banerjee T, Singh AK, Sharma RK, Maitra AN. Labeling efficiency and biodistribution of technetium-99m labeled nanoparticles: Interference by colloidal tin oxide particles. Int J Pharm 2005; 289: 189–195
   PubMedGoogle Scholar
• Blomer U, Ganser A, Scherr M. Invasive drug delivery. Adv Exp Med Biol 2002; 513: 431–451
   PubMed Web of Science ®Google Scholar
• Borchard G, Audus KL, Shi F, Kreuter J. Uptake of surfactant coated poly (methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 1994; 110: 29–35
   Web of Science ®Google Scholar
• Chen Y, Dalwadi G, Benson HA. Drug delivery across the blood–brain barrier. Curr Drug Deliv 2004; 1(4)361–376
   PubMedGoogle Scholar
• Das D, Lin S. Double coated poly (butylcyanoacrylate) nanoparticulate delivery system for brain targeting of dalargin via oral administration. J Pharm Sci 2005; 94(6)1343–1353
   PubMed Web of Science ®Google Scholar
• Demeule M, Regina A, Annabi B, Bertrand Y, Bojanowski MW, Beliveau R. Brain endothelial cells as pharmacological targets in brain tumors. Mol Neurobiol 2004; 30(2)157–183
   PubMed Web of Science ®Google Scholar
• Gallia GL, Brem S, Brem H. Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Cancer Netw 2005; 3(5)721–728
   PubMedGoogle Scholar
• Gozzi A, Schwarz AJ, Reese T, Crestan V, Bertani S, Turrini G, Corsi M, Bifone A. Functional magnetic resonance mapping of intracerebroventricular infusion of a neuroactive peptide in the anaesthetised rat. J Neurosci Methods 2005; 142(1)115–124
   PubMed Web of Science ®Google Scholar
• Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of Doxorubicin into the brain with polysorbate80 coated nanoparticles. Pharm Res 1999; 16: 1564–1569
   PubMed Web of Science ®Google Scholar
• Gupta AK, Madan Sumit, Majumdar DK, Maitra Amarnath. Ketorolac entrapped in polymeric micelles: Preparation, characterization and ocular anti-inflammatory studies. Int J Pharm 2000; 209: 1–14
   PubMed Web of Science ®Google Scholar
• Haluska M, Anthony ML. Osmotic blood–brain barrier modification for the treatment of malignant brain tumors. Clin J Oncol Nurs 2004; 8(3)263–267
   PubMedGoogle Scholar
• Iigo M, Hoshi A, Nakamura A, Kuretani. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors. Cancer Chemother Pharmacol 1978; 1(4)203–208
   PubMed Web of Science ®Google Scholar
• Kreuter J. Evaluation of nanoparticles as drug-delivery systems. III: Materials, stability toxicity, possibilities of targeting, and use. Pharm Acta Helv 1983; 58: 242–250
   PubMedGoogle Scholar
• Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after it's delivery across the blood–brain barrier using surfactant coated nanoparticles. J Control Release 1997; 49: 81–87
   Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65–81
   PubMed Web of Science ®Google Scholar
• Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. Curr Med Chem Cent Nerv Syst Agents 2002; 2(3)241–249
   Google Scholar
• Kumar S, Chuttani K, Kumar N, Sharma RK, et al. Radiolabeling and evaluation of 99mTc labeled 5-fluorouracil as a tumor marker. Indian J Nucl Med 2004; 19(4)128
   Google Scholar
• Lockman PR, Koziara J, Roder KE, Paulson J, Abbruscato TJ, et al. In vivo and in vitro assessment of baseline blood–brain barrier parameters in the presence of novel nanoparticles. Pharm Res 2003; 20(5)705–713
   PubMed Web of Science ®Google Scholar
• Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005; 76(1)22–76
   PubMed Web of Science ®Google Scholar
• Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchellli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80 coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999; 16: 1836–1842
   PubMed Web of Science ®Google Scholar
• Olivier JC. Drug transport to brain with targeted nanoparticles. Neurorx 2005; 2(1)108–119
   PubMedGoogle Scholar
• Ozaki S, Ike Y, Mizuno H, Ishikawa K, Mori H. 5-Fluorouracil derivatives. 1. The synthesis of 1-carbamoyl-5-fluorouracils. Bull Chem Soc Jpn 1977; 50(9)2406–2412
   Web of Science ®Google Scholar
• Pardridge WM. Intravenous, non-viral RNAi gene therapy of brain cancer. Expert Opin Biol Ther 2004; 4(7)1103–1113, Review
   PubMed Web of Science ®Google Scholar
• Paul G. Cell transplantation for patients with Parkinson's disease. Handb Exp Pharmacol 2006, 174: 361–388
   PubMedGoogle Scholar
• Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. Neurorx 2005; 2(1)99–107
   PubMedGoogle Scholar
• Sikorski CW, Lesniak MS. Immunotherapy for malignant glioma: Current approaches and future directions. Neurol Res 2005; 27(7)703–716
   PubMed Web of Science ®Google Scholar
• Soni S, Babbar AK, Sharma RK, Banerjee T, Maita AN. Pharmacoscintigraphic evaluation of polysorbate80 coated chitosan nanoparticles for brain targeting. Am J drug target 2005; 3(3)205–212
   Google Scholar
• Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin loaded nanoparticles. Int J Cancer 2004; 109(5)759–767
   PubMed Web of Science ®Google Scholar
• Troster SD, Muller U, Kreuter J. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int J Pharm 1990; 61: 85–100
   Web of Science ®Google Scholar
• Tyagi R, Lala S, Verma AK, Nandy AK, Mahato SB, Maitra A, Basu MK. Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasi. J Drug Target 2005; 13(3)161–171
   PubMed Web of Science ®Google Scholar
• Woodcock DM, Linsenmeyer ME, Chojnowski G, et al. Reversal of multi drug resistance by surfactants. Br J Cancer 1992; 66(1)62–68
   PubMed Web of Science ®Google Scholar
• Yang W, Barth RF, Bartus RT, Rotaru JH, Moeschberger ML, Ferketich AK, Nawrocky MM, Coderre JA, Goodman JH. Improved survival after boron neutron capture therapy of brain tumors by Cereport-mediated blood–brain barrier modulation to enhance delivery of boronophenylalanine. Neurosurgery 2000; 47(1)189–197, discussion 197–8
   PubMed Web of Science ®Google Scholar